## COR: Cencora, Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 1.5% below STRENGTH zone (3.0-6.0%). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($326.89)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 9, Bearish: 0)

**1. Cencora to acquire majority stake in OneOncology for $5B**
- Source: Fierce Healthcare | 20251216T170807 | Bullish | Relevance: 100%
- Cencora is set to acquire a majority stake in OneOncology for $5 billion, accelerating its buyout of the specialty practice network. This strategic move, which values OneOncology at $7.4 billion, will see Cencora controlling the majority interest while OneOncology’s affiliated practices retain a minority share. The deal is expected to close by the end of Q1 2026 and aligns with Cencora's pharmaceutical-centric growth strategy, enhancing its distribution avenues and operational support for oncology practices.

**2. Cencora to Acquire TPG’s Equity Stake in OneOncology, Strengthening Specialty Care Platform**
- Source: Digital Health News | 20251216T110814 | Bullish | Relevance: 100%
- Cencora has announced a definitive agreement to acquire TPG's equity stake in OneOncology, a national platform supporting independent oncology practices. This acquisition is set to accelerate OneOncology's growth by expanding technology capabilities, clinical innovation, and shared services. Both Cencora and TPG expressed confidence that this move will strengthen specialty care and continue OneOncology's success in delivering accessible and innovative oncology care.

**3. Cencora Should See Double-Digit Long-term EPS Growth from Market Growth and Specialty Investments**
- Source: Morningstar | 20251215T200841 | Bullish | Relevance: 100%
- Cencora, a leading pharmaceutical wholesaler, is projected to achieve double-digit long-term EPS growth due to overall market expansion and strategic investments in specialty products. The company, alongside Cardinal Health and McKesson, forms an oligopoly that controls over 90% of the US drug distribution market, ensuring a strong competitive position. Recent moves, including the OneOncology investment, are seen as strategically sound for sustained growth.

**4. Cencora Moves To Take Full Control Of OneOncology**
- Source: Finimize | 20251215T160826 | Bullish | Relevance: 100%
- Cencora is acquiring nearly all of OneOncology for $5 billion, deepening its involvement in the growing US cancer care market. This move transitions Cencora from a minority to a controlling stake, aiming for long-term adjusted earnings growth despite initial neutrality. The deal signifies Cencora’s commitment to specialized healthcare and accelerates consolidation within the cancer care landscape.

**5. Cencora to buy majority of OneOncology's outstanding equity**
- Source: Axios | 20251215T160758 | Bullish | Relevance: 100%
- Cencora plans to acquire most of OneOncology's outstanding equity that it doesn't already own, including shares from TPG, for roughly $5 billion. This acquisition values the cancer practice network OneOncology at approximately $7.4 billion.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 0, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-09 | Barclays | $400 | $0 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-09 | Barclays | init | Overweight |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 47.0% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 3 |

**Top Holders:**
- Vanguard Group Inc: 12.1% (+4.1%)
- Blackrock Inc.: 10.2% (+5.7%)
- JPMORGAN CHASE & CO: 4.8% (+139.5%)
- State Street Corpora: 4.7% (+9.3%)
- Price (T.Rowe) Assoc: 4.0% (-0.9%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- Momentum building: MRS_10 improving +4.3% over 5 days suggests accumulation.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 0.92 indicates undervaluation relative to growth. Quality metrics strong (ROE 124%). Balance sheet: $2.9B free cash flow. Institutional flow bullish (7 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $66.3B |
| Beta | 0.63 |
| 52W Range | $223.92 - $377.54 |
| Short Interest | 4.1% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.92 |
| Forward P/E | 17.5 |
| Current P/E | 19.4 |
| YoY Growth | 11.0% |
| EPS Direction | STABLE |

### Technicals

MRS_10 strengthening from -2.8% to 1.5% (+4.3% in 5 days), confirming momentum buildup. Below STRENGTH zone by 1.5pp (needs >3.0% for momentum thesis). MRS_5 at 0.0% confirms short-term momentum alignment. Long-term uptrend intact (above SMA200 at 1.13x) but short-term weakness (below SMA20). MACD histogram bearish (-1.82), momentum weakening. RSI neutral at 44. OFD pattern: -MTL (Decline).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 1.50% (CS: 57) | Neutral |
| RSI_14 | 44.3 | Neutral |
| MACD Histogram | -1.82 | Bearish |
| vs SMA20 | 0.968x | Below |
| vs SMA50 | 0.994x | Below |
| vs SMA200 | 1.132x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $341.61
- **Stop Loss:** $326.89 (4.3% risk)
- **Target:** $356.33 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 67
- **Position Value:** $22,887.87
- **Portfolio %:** 22.89%
- **Risk Dollars:** $1,000.00
- **Risk Per Trade:** 1.00%
- **Modifiers:** L1 100% | L2 100% | Combined 1.00x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with balanced risk positioning. VIX remains calm at 16.48 while breadth shows modest improvement to 52%, indicating neither euphoria nor distress. Mixed sectoral themes from energy weakness to AI expansion suggest stock-picking environment rather than broad directional moves.*

### Earnings

**Next:** 2026-02-04 (Est: $4.07)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $3.79 | $3.84 | +1.4% |
| 2025Q2 | $3.84 | $4.00 | +4.2% |
| 2025Q1 | $4.10 | $4.42 | +7.9% |
| 2024Q4 | $3.52 | $3.73 | +6.0% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*